Legend Biotech Corporation provided earnings guidance for the six months ended June 30, 2022. For the six months, the company expects to record a loss of approximately USD 196 million to USD 228.9 million and an adjusted loss for the period of approximately USD 144.5 million to USD 168.6 million, in each case, including research and development expenses of approximately USD 135.3 million to USD 157.9 million, which was mainly caused by the continuous investment into its lead product candidate, ciltacabtagene autoleucel (cilta-cel), and other product candidates in Legend Biotech's pipeline.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
45.16 USD | -2.61% | +4.44% | -24.95% |
May. 15 | Legend Expects to Log Profit in 2026 | MT |
May. 14 | HC Wainwright Adjusts Price Target on Legend Biotech to $86 From $87, Keeps Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-24.95% | 8.23B | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.87B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- LEGN Stock
- News Legend Biotech Corporation
- Legend Biotech Corporation Provides Earnings Guidance for the Six Months Ended June 30, 2022